TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Blinklab Limited ( (AU:BB1) ).
BlinkLab Limited has partnered with the University of Missouri’s Thompson Center for Autism & Neurodevelopment as a clinical research site for its pivotal FDA 510(k) diagnostic trial for BlinkLab Dx 1. This collaboration marks the commencement of the main study phase following a successful pilot phase. The Thompson Center is renowned for its expertise in neurodevelopmental disorders, making it a valuable partner in ensuring high scientific and clinical standards. The trial is expected to conclude in Q2 2026, with final FDA submission anticipated in Q3 2026, potentially influencing the adoption and commercialization of BlinkLab Dx 1.
More about Blinklab Limited
BlinkLab Limited is a leading digital healthcare company specializing in AI-powered diagnostics. The company focuses on developing innovative diagnostic aids, such as BlinkLab Dx 1, a smartphone-based tool aimed at detecting autism spectrum disorder.
Average Trading Volume: 220,915
Technical Sentiment Signal: Buy
For an in-depth examination of BB1 stock, go to TipRanks’ Overview page.